---
layout: default
title: Ribociclib Succinate
parent: 僅模型預測 (L5)
nav_order: 70
evidence_level: L5
indication_count: 0
---

# Ribociclib Succinate
{: .fs-9 }

證據等級: **L5** | 預測適應症: **0** 個
{: .fs-6 .fw-300 }

---

## 目錄
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## 藥師評估報告

</div>

# Ribociclib Succinate: Drug Repurposing Evaluation — Insufficient Data

## One-Sentence Summary

Ribociclib succinate is a pharmaceutical compound queried in this evaluation pipeline; however, the current Evidence Pack contains no original indication records and no TxGNN-predicted new indications. Due to multiple blocking data gaps, a full repurposing assessment cannot be completed at this stage.

---

## Quick Overview

| Item | Content |
|------|---------|
| Original Indication | Not retrieved in this Evidence Pack |
| Predicted New Indication | No TxGNN predictions available |
| TxGNN Prediction Score | — |
| Evidence Level | L5 (model prediction not available; no supporting studies) |
| Taiwan Market Status | Not marketed (0 licenses) |
| Number of Authorizations | 0 |
| Recommended Decision | **Hold** |

---

## Why is This Prediction Reasonable?

No TxGNN predicted indications were returned in this Evidence Pack (`predicted_indications: []`). Without a target indication, mechanistic applicability analysis cannot be performed.

Additionally, the mechanism of action (MOA) field is absent from the current data retrieval. The DrugBank query returned one result (per query log entry #3), but the structured MOA field was not populated — this likely requires a follow-up DrugBank API call to extract pharmacological category, target proteins, and pathway data.

The TFDA package insert query also returned one result (query log entry #4), yet no warnings, contraindications, or indication text were parsed into the Evidence Pack. Resolution of these two data gaps is prerequisite to any repurposing analysis.

---

## Safety Considerations

All safety fields returned no usable data in this Evidence Pack. No drug-drug interactions were identified (DDI query status: not found). Please refer to the official package insert for warnings, contraindications, and interaction information.

---

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
The Evidence Pack contains no predicted indications and no original indication data, making it impossible to assess repurposing plausibility, clinical evidence, or safety profile at this time.

**To proceed, the following is needed:**

- **[Blocking]** Re-run TxGNN prediction pipeline for Ribociclib Succinate and confirm `predicted_indications` is populated before any downstream analysis
- **[Blocking]** Parse TFDA package insert (query log #4 returned success) to extract approved indications, warnings, and contraindications
- **[High]** Query DrugBank API (query log #3 returned success) to extract MOA, drug categories, and toxicity data — specifically needed to determine CDK4/6 inhibitor classification and cytotoxicity status
- **[High]** Confirm DrugBank ID (`drugbank_id: null`) to enable structured data retrieval
- **[Medium]** Re-run DDI query after DrugBank ID is resolved
- Once above gaps are resolved, re-generate Evidence Pack and re-run this report template
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

